- $8.10m
- -$8.33m
- $5.90m
- 22
- 52
- 54
- 38
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 9.27 | 7.38 | 8.25 | 8.26 | 5.9 |
Cost of Revenue | |||||
Gross Profit | 2.25 | 5.25 | 5.92 | 5.75 | 3.95 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 13.1 | 9.47 | 10.5 | 13 | 13.1 |
Operating Profit | -3.82 | -2.09 | -2.28 | -4.74 | -7.15 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -3.77 | -2.09 | -2.28 | -4.42 | -6.53 |
Net Income After Taxes | -3.77 | -2.09 | -2.28 | -4.42 | -6.53 |
Net Income Before Extraordinary Items | |||||
Net Income | -3.77 | -2.09 | -2.28 | -4.42 | -6.53 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -3.77 | -2.09 | -2.28 | -4.42 | -6.53 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -89 | -4.62 | -3.37 | -4.96 | -6.27 |